Gandjour, Afschin; Schüßler, Sofia; Hammerschmidt, Thomas - In: The European Journal of Health Economics 21 (2020) 7, pp. 1049-1057
Introduction In Germany, all new, innovative medicines are subject to an early benefit assessment by the German Federal … drivers of negotiated (including arbitrated) prices of new, non-orphan innovative medicines in Germany. Methods The analysis …